Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies-Reference-Cited by-同舟云学术

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies

Published:2016-11 Issue:11 Volume:11 Page:2022-2026
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Campo Meghan,Gerber David,Gainor Justin F.,Heist Rebecca S.,Temel Jennifer S.,Shaw Alice T.,Fidias Panos,Muzikansky Alona,Engelman Jeffrey A.,Sequist Lecia V.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference13 articles.

1. Non small cell lung cancer, version 1.2015;Ettinger;J Natl Compr Canc Netw,2014

2. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

3. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers;Yu;Clin Cancer Res,2013

4. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J Clin Oncol,2013

5. BIBW2992, an irreversible EGFR/HER2 Inhibitor highly effective in preclinical lung cancer models;Li;Oncogene,2008

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing intracranial efficacy prediction of osimertinib in non-small cell lung cancer: a novel approach through brain MRI radiomics;Frontiers in Neurology;2024-08-30

2. A breast cancer targeted photodynamic degrader to activate immunotherapy through EGFR degradation mediated PD-L1 downregulation;Chemical Engineering Journal;2024-05

3. Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer;International Journal of Molecular Sciences;2024-01-09

4. Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC;Therapeutic Advances in Medical Oncology;2024-01

5. Saturation resistance profiling of EGFR variants against tyrosine kinase inhibitors using prime editing;2023-12-05